Drug Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Drug Name Aldesleukin
Trade Name Proleukin
Synonyms IL-2
Drug Descriptions

Aldesleukin (IL-2) is a cytokine that potentially modulates antitumor immune response (NCI Drug Dictionary).

DrugClasses

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
Aldesleukin Aldesleukin 0 26
Aldesleukin + Alpha 2 Interferon + Vemurafenib Aldesleukin Alpha 2 Interferon Vemurafenib 0 1
Aldesleukin + Anti-hCD70 CAR T cells Aldesleukin Anti-hCD70 CAR T cells 0 1
Aldesleukin + Anti-IL13RA2 CAR T cells + Cyclophosphamide + Fludarabine Aldesleukin Anti-IL13RA2 CAR T cells Cyclophosphamide Fludarabine 0 1
Aldesleukin + anti-KRAS G12D mTCR cells + Cyclophosphamide + Fludarabine Aldesleukin Cyclophosphamide Fludarabine anti-KRAS G12D mTCR cells 0 1
Aldesleukin + Anti-MAGE-A3-DP4 TCR T-cells + Cyclophosphamide + Fludarabine Aldesleukin Anti-MAGE-A3-DP4 TCR T-cells Cyclophosphamide Fludarabine 0 1
Aldesleukin + Anti-NY ESO-1 mTCR PBL + Cyclophosphamide + Fludarabine Aldesleukin Anti-NY ESO-1 mTCR PBL Cyclophosphamide Fludarabine 0 1
Aldesleukin + Anti-NY ESO-1 mTCR PBL + Cyclophosphamide + Fludarabine + NY-ESO-1 peptide vaccine Aldesleukin Anti-NY ESO-1 mTCR PBL Cyclophosphamide Fludarabine NY-ESO-1 peptide vaccine 0 1
Aldesleukin + Bevacizumab Aldesleukin Bevacizumab 0 1
Aldesleukin + CMB305 + Cyclophosphamide + ID-LV305 Aldesleukin CMB305 Cyclophosphamide ID-LV305 0 1
Aldesleukin + Cyclophosphamide Aldesleukin Cyclophosphamide 0 1
Aldesleukin + Cyclophosphamide + Decitabine + NY-ESO-1-c259T Aldesleukin Cyclophosphamide Decitabine NY-ESO-1-c259T 0 1
Aldesleukin + Cyclophosphamide + Fludarabine Aldesleukin Cyclophosphamide Fludarabine 0 5
Aldesleukin + Cyclophosphamide + Fludarabine + FT516 Aldesleukin Cyclophosphamide FT516 Fludarabine 0 1
Aldesleukin + Cyclophosphamide + Fludarabine + FT516 + Obinutuzumab Aldesleukin Cyclophosphamide FT516 Fludarabine Obinutuzumab 0 1
Aldesleukin + Cyclophosphamide + Fludarabine + FT516 + Rituximab Aldesleukin Cyclophosphamide FT516 Fludarabine Rituximab 0 1
Aldesleukin + Cyclophosphamide + Fludarabine + IMA101 T cells Aldesleukin Cyclophosphamide Fludarabine IMA101 T cells 0 1
Aldesleukin + Cyclophosphamide + Fludarabine + iTCR-transduced PBL Aldesleukin Cyclophosphamide Fludarabine iTCR-transduced PBL 0 1
Aldesleukin + Cyclophosphamide + Fludarabine + iTCR-transduced PBL + Pembrolizumab Aldesleukin Cyclophosphamide Fludarabine Pembrolizumab iTCR-transduced PBL 0 1
Aldesleukin + Cyclophosphamide + Fludarabine + LN-145 + Pembrolizumab Aldesleukin Cyclophosphamide Fludarabine LN-145 Pembrolizumab 0 1
Aldesleukin + Cyclophosphamide + Fludarabine + MDA autologous tumor-infiltrating lymphocytes Aldesleukin Cyclophosphamide Fludarabine MDA autologous tumor-infiltrating lymphocytes 0 1
Aldesleukin + Cyclophosphamide + Fludarabine + Mesna + Pembrolizumab Aldesleukin Cyclophosphamide Fludarabine Mesna Pembrolizumab 0 1
Aldesleukin + Cyclophosphamide + Fludarabine + NGFR-transduced autologous T lymphocytes + TGFbDNRII-transduced autologous TILs Aldesleukin Cyclophosphamide Fludarabine NGFR-transduced autologous T lymphocytes TGFbDNRII-transduced autologous TILs 0 1
Aldesleukin + Cyclophosphamide + Fludarabine + Pembrolizumab Aldesleukin Cyclophosphamide Fludarabine Pembrolizumab 0 1
Aldesleukin + Cyclophosphamide + Fludarabine + RV-NY-ESO TCR PBMC Aldesleukin Cyclophosphamide Fludarabine RV-NY-ESO TCR PBMC 0 0
Aldesleukin + Cyclophosphamide + ID-LV305 Aldesleukin Cyclophosphamide ID-LV305 0 1
Aldesleukin + Cyclophosphamide + Ipilimumab Aldesleukin Cyclophosphamide Ipilimumab 0 1
Aldesleukin + Cyclophosphamide + Naxitamab Aldesleukin Cyclophosphamide Naxitamab 0 1
Aldesleukin + Cyclophosphamide + Pembrolizumab Aldesleukin Cyclophosphamide Pembrolizumab 0 1
Aldesleukin + Cyclophosphamide + Utomilumab Aldesleukin Cyclophosphamide Utomilumab 0 1
Aldesleukin + EGFRBi-armed autologous activated T cells + Sargramostim Aldesleukin EGFRBi-armed autologous activated T cells Sargramostim 0 1
Aldesleukin + FATE-NK100 Aldesleukin FATE-NK100 0 1
Aldesleukin + GD2Bi-aATC + Sargramostim Aldesleukin GD2Bi-aATC Sargramostim 0 1
Aldesleukin + IMA201 Aldesleukin IMA201 0 1
Aldesleukin + Ipilimumab Aldesleukin Ipilimumab 0 1
Aldesleukin + LV-NY-ESO TCR/sr39TK PBSC + RV-NY-ESO TCR PBMC Aldesleukin LV-NY-ESO TCR/sr39TK PBSC RV-NY-ESO TCR PBMC 0 2
Aldesleukin + Melphalan + Sargramostim Aldesleukin Melphalan Sargramostim 0 1
Aldesleukin + Nivolumab Aldesleukin Nivolumab 0 2
Aldesleukin + Pembrolizumab Aldesleukin Pembrolizumab 0 5
Aldesleukin + Pembrolizumab + Radiotherapy Aldesleukin Pembrolizumab Radiotherapy 0 1
Aldesleukin + Vemurafenib Aldesleukin Vemurafenib 0 2


Additional content available in CKB BOOST